Phase 2 Trial of 5-Fluorouracil, Oxaliplatin, Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-Positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma

This study is being done to find out whether adding a drug called liposomal irinotecan to
standard combination therapy will be more active against advanced EGA than standard
treatment. Liposomal irinotecan is a new chemotherapy drug that has been approved by
the FDA to treat pancreatic cancer. Researchers think that combining liposomal
irinotecan with a standard combination chemotherapy regimen will be beneficial against
EGA as well. Combining three chemotherapy drugs has been shown to be more potent
against this cancer in the past. However, older drugs have had more side effects.
Researchers hope that the new combination will be active and less toxic. However, this
treatment may have bad side effects, even if it shrinks tumors.